Pulmonx Corporation announced it will release its third quarter 2026 financial results after market close on October 27, 2026. The company will hold a conference call at 1:30 p.m. PT / 4:30 p.m. ET to discuss the results, which will be available via webcast on its investor website. Pulmonx is known for its minimally invasive treatments for severe lung diseases, including its FDA-approved Zephyr Valve for COPD patients. This earnings report will provide investors insight into the company's recent performance and outlook.
Pulmonx Corporation's upcoming Q3 2026 financial report is noted here for context. For readers following the health sector, 28 of 128 US health stocks on Pluang rose while 100 fell as of Oct 14, 2026 03:02 WIB. Johnson & Johnson traded at USD 248.76 with a 5.68% drop, Citius Pharmaceuticals Inc at USD 0.47 with a 5.60% drop, and Heron Therapeutics Inc at USD 0.39 with a 5.32% drop.
Applied Materials projects sustained demand for its chipmaking equipment driven by AI infrastructure growth, expecting faster spending on wafer fab equipment through 2030. The company aims to increase its market share by over 2 percentage points from...
Gordon Haskett Capital Corporation set a $105 price target for Ollie's Bargain Outlet, suggesting an 18.1% upside from its current price around $89. The company’s board approved an additional $500 million share repurchase authorization, increasing to...
FRUIT Holdings, Inc. introduced PAVE, a new protocol designed to allow AI systems to call on human judgment and authority when needed. This approach ensures that human input retains its value, authority, and attribution within AI workflows, addressin...
AngioDynamics reported a 6.9% revenue increase to $80.9 million and a narrowed adjusted loss of 4 cents per share for Q1 fiscal 2027, with strong Med Tech sales growing 13.2%. Despite beating earnings expectations and improved gross margin, the stock...
Domino's Pizza reported Q3 2026 earnings per share of $4.60, beating analyst expectations of $4.37, while revenue grew modestly by 3.4% to $1.19 billion. Same-store sales growth was minimal at 0.3% in the U.S. and 0.2% internationally, reflecting com...
